AKYNZEO: payments to doctors
Payments that named AKYNZEO as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $205K
- Providers
- 1,202
- Transactions
- 2,738
- Average per transaction
- $75
The per-transaction average — $75 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 1,202 providers the average total is $171, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Helsinn Therapeutics (U.S.), Inc. | $94,003 | 45.8% |
| Helsinn Healthcare SA | $92,126 | 44.8% |
| Vifor (international) Ltd. | $16,501 | 8.0% |
| Verity Pharmaceuticals Inc. | $2,781 | 1.4% |